-
AstraZeneca hikes divided as drugmaker's investors prepare to vote on chief executive's £18.7m pay package
11 Apr 2024 07:59 GMT
… on the firm's chief executive's controversial bumper pay … Partners said the French-Australian chief executive has earned the right to … for the expanded use of Daiichi Sankyo and AstraZeneca's drug …
-
Gilead writes $2.4B off Trodelvy as CEO underscores 'time of focused execution'
26 Apr 2024 18:20 GMT
… clinical data as AstraZeneca and Daiichi Sankyo are closing in on an … Trodelvy developments accentuates what Gilead CEO Dan O’Day called “a …
-
AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for En...
08 Apr 2024 17:20 GMT
… on Friday approved AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu … tumor-agnostic indication, AstraZeneca and Daiichi Sankyo will need to run a … to verify its clinical benefit.
Daiichi Sankyo CEO Ken Keller in a statement …
-
AstraZeneca/Daiichi Sankyo’s Enhertu granted FDA accelerated approval for solid tumours
08 Apr 2024 11:41 GMT
AstraZeneca (AZ) and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has … oncology business, and president and chief executive officer, Daiichi Sankyo, added: “This fifth indication …
-
AstraZeneca CEO says platform deals largely done after M&As in vaccines, radioligand, cell therapy
25 Apr 2024 17:59 GMT
… stretching too thin.
To hear CEO Pascal Soriot explain it, the … also the long term,” the chief executive said.
But M&A … between AZ and its partner Daiichi Sankyo. The antibody-drug conjugate enjoyed …
-
AstraZeneca and Daiichi Sankyo’s drug gets USFDA nod for people with HER2-positive solid tumours
08 Apr 2024 10:12 GMT
… ADC) discovered by Daiichi Sankyo and being jointly … business, and president and CEO, Daiichi Sankyo, Inc., said.
… .
Daiichi Sankyo Company, Limited [referred to as Daiichi Sankyo] and … Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is …
-
AstraZeneca and Daiichi Sankyo's Enhertu Approved in the US
08 Apr 2024 09:51 GMT
AstraZeneca and Daiichi Sankyo's Enhertu … (ADC) discovered by Daiichi Sankyo and being jointly developed … commercialised by AstraZeneca and Daiichi Sankyo.
The first tumour- … Oncology Business, and President and CEO, Daiichi Sankyo, Inc., said: “This …
-
AstraZeneca & Daiichi Sankyo's Enhertu gets US FDA nod for previously treated patients with metastatic HER2─positive solid tumours
08 Apr 2024 03:51 GMT
… by AstraZeneca and Daiichi Sankyo.
The first tumour … business, and president and CEO, Daiichi Sankyo, Inc., said: “ … .
Daiichi Sankyo Company, Limited [referred to as Daiichi Sankyo] … Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is …
-
AstraZeneca-Daiichi Sankyo Enhertu gets USFDA accelerated nod for metastatic HER2-positive solid tumours
07 Apr 2024 10:05 GMT
… (ADC) discovered by Daiichi Sankyo and being jointly developed … commercialised by AstraZeneca and Daiichi Sankyo.
The first tumour- … Business, and President and CEO, Daiichi Sankyo, Inc., said, “This … US are recognised by Daiichi Sankyo. AstraZeneca reports its …
-
Daiichi Sankyo : ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2 Positive Solid Tumors (375.5KB
06 Apr 2024 06:42 GMT
… , and President and CEO, Daiichi Sankyo, Inc. " … the Daiichi Sankyo and AstraZeneca Collaboration
Daiichi Sankyo and … Daiichi Sankyo maintains exclusive rights for each ADC. Daiichi Sankyo … developed by Daiichi Sankyo.
Designed using Daiichi Sankyo's …